 |
        |
 |
||||||
 |
 |
ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.
 |
|
Canaan Partners Closes $600 Million Fund, Canaan IX
January 9, 2012 - Click to Read More ORTHOCON® Announces Signing of Exclusive, Worldwide License Agreement with Bezwada Biomedical August 31, 2011 - Click to Download |
||
|
||||||
